HOME > BUSINESS
BUSINESS
- GSK, Kyowa Kirin Join Hands for HIF-PH Inhibitor Daprodustat
November 26, 2018
- Astellas Grabs License to Gene Therapy JVS-100, with Acquisition also in Cards
November 26, 2018
- Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
November 26, 2018
- Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
- MHLW Approves Label Expansions for Praluent, Tremfya
November 22, 2018
- Mundipharma Obtains Exclusive Rights in Japan from South Korean Firm for Osteoarthritis Cell Therapy
November 22, 2018
- Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring
November 22, 2018
- Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
- Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan
November 21, 2018
- AbbVie Seeks Japan Approval for BCL-2 Inhibitor Venetoclax in CLL
November 21, 2018
- Takeda to Issue US$5.5 Billion in Bonds for Shire Acquisition
November 21, 2018
- Mitsubishi Tanabe Cuts FY2020 Targets in 5-Year Biz Plan on Flagging Royalty, Development Delay
November 21, 2018
- Sawai to Attach More Weight to Profits, Received Several Approaches for Possible Tie-Up: Chief
November 20, 2018
- Amgen Astellas’ Migraine Drug Hits Primary Endpoint in Japan PII
November 20, 2018
- 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision
November 20, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
- High Court Upholds Not-Guilty Ruling for Novartis, Ex-Employee in Diovan Case
November 20, 2018
- Toray to Develop Small Molecule Cancer Drug Licensed from US Bioventure
November 20, 2018
- Chugai Sues Alexion in US over Soliris Successor ALXN1210
November 19, 2018
- 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs
November 19, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
